Trial Profile
Efficacy of a human anti-RANKL antibody (Denosumab) on prevention of steroid-induced osteoporosis in patients with autoimmune hepatitis (AIH)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2016
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Corticosteroid-induced osteoporosis
- Focus Therapeutic Use
- 07 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Jul 2014 New trial record